Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04199026 · ClinicalTrials.gov registry record · NA
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
A NA study of Metastatic Sarcoma and Recurrent Sarcoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04199026 is a NA study of Metastatic Sarcoma and Recurrent Sarcoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants, below the 40-participant average among 12 other Metastatic Sarcoma trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04199026, a NA study of Metastatic Sarcoma and Recurrent Sarcoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delivered in the microdevice affect tumor tissue in patients with sarcomas.
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Doxorubicin Hydrochloride
- DEVICE Drug Delivery Microdevice
- DRUG Everolimus
- BIOLOGICAL Ganitumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04199026
The ClinicalTrials.gov registry entry for NCT04199026 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 40-participant average among 12 other Metastatic Sarcoma trials with a reported enrollment target (50% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which Doxorubicin is the first listed.
NCT04199026 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04199026 about?
NCT04199026 is a clinical study titled "Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma". This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 1...
What is the current status of trial NCT04199026?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-02-25. Estimated completion is 2028-12-31.
What conditions does trial NCT04199026 study?
This clinical trial studies the following conditions: Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma.
What interventions are being tested in trial NCT04199026?
The interventions under investigation include: Doxorubicin (DRUG), Doxorubicin Hydrochloride (DRUG), Drug Delivery Microdevice (DEVICE), Everolimus (DRUG), Ganitumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04199026?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04199026 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
-
A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma
RECRUITING · NA
-
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
RECRUITING · NA
-
Intravital Microscopy in Human Solid Tumors
RECRUITING · NA
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.